BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33352174)

  • 1. Impact of Multimodality Treatment Sequence on Survival in Stage IIB Non-Small Cell Lung Cancer.
    Stokes SM; Massarweh NN; Stringham JR; Varghese TK
    Ann Thorac Surg; 2021 Nov; 112(5):1559-1567. PubMed ID: 33352174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung Cancer.
    Bott MJ; Patel AP; Crabtree TD; Morgensztern D; Robinson CG; Colditz GA; Waqar S; Kreisel D; Krupnicka AS; Patterson GA; Broderick S; Meyers BF; Puri V
    Ann Thorac Surg; 2015 Jun; 99(6):1921-8. PubMed ID: 25912748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.
    Uhlig J; Case MD; Blasberg JD; Boffa DJ; Chiang A; Gettinger SN; Kim HS
    JAMA Netw Open; 2019 Aug; 2(8):e199702. PubMed ID: 31433481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-Year Survival Among Stage IIIA Lung Cancer Patients Receiving Two Different Treatment Modalities.
    Bilfinger T; Keresztes R; Albano D; Nemesure B
    Med Sci Monit; 2016 Jul; 22():2589-94. PubMed ID: 27442604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
    Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
    Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the fate of patients who undergo resections of very large, node-negative lung cancers using the National Cancer DataBase.
    Liu J; Hancock JG; Moreno AC; Wang Z; Boffa DJ; Detterbeck FC; Kim AW
    Eur J Cardiothorac Surg; 2016 Feb; 49(2):596-601. PubMed ID: 25890936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemoradiation Shows No Survival Advantage to Chemotherapy Alone in Stage IIIA Patients.
    Krantz SB; Mitzman B; Lutfi W; Kuchta K; Wang CH; Howington JA; Kim KW
    Ann Thorac Surg; 2018 Apr; 105(4):1008-1016. PubMed ID: 29453000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer.
    Sher DJ; Fidler MJ; Liptay MJ; Koshy M
    Lung Cancer; 2015 Jun; 88(3):267-74. PubMed ID: 25862147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
    Brandt WS; Yan W; Zhou J; Tan KS; Montecalvo J; Park BJ; Adusumilli PS; Huang J; Bott MJ; Rusch VW; Molena D; Travis WD; Kris MG; Chaft JE; Jones DR
    J Thorac Cardiovasc Surg; 2019 Feb; 157(2):743-753.e3. PubMed ID: 30415902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.
    Vyfhuis MAL; Burrows WM; Bhooshan N; Suntharalingam M; Donahue JM; Feliciano J; Badiyan S; Nichols EM; Edelman MJ; Carr SR; Friedberg J; Henry G; Stewart S; Sachdeva A; Pickering EM; Simone CB; Feigenberg SJ; Mohindra P
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):445-452. PubMed ID: 29559292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer.
    Gao SJ; Corso CD; Wang EH; Blasberg JD; Detterbeck FC; Boffa DJ; Decker RH; Kim AW
    J Thorac Oncol; 2017 Feb; 12(2):314-322. PubMed ID: 27720827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Chemotherapy Improves Survival in pN-positive Clinical Stage IIIA Non-Small Cell Lung Cancer After Neoadjuvant Therapy and Resection.
    Atay SM; Amini M; Ding L; David EA; Mcfadden PM; Wightman SC; Kim AW
    Ann Thorac Surg; 2021 Jul; 112(1):197-205. PubMed ID: 33121965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimodality vs Chemoradiation and Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung Cancer.
    Ye JC; Ding L; Atay SM; Nieva JJ; McFadden PM; Chang E; Kim AW
    Semin Thorac Cardiovasc Surg; 2020; 32(1):153-159. PubMed ID: 31220530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter?
    Samson P; Patel A; Crabtree TD; Morgensztern D; Robinson CG; Colditz GA; Waqar S; Kreisel D; Krupnick AS; Patterson GA; Broderick S; Meyers BF; Puri V
    Ann Thorac Surg; 2015 Nov; 100(5):1773-9. PubMed ID: 26228601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall.
    Gao SJ; Corso CD; Blasberg JD; Detterbeck FC; Boffa DJ; Decker RH; Kim AW
    Clin Lung Cancer; 2017 Mar; 18(2):169-177.e4. PubMed ID: 27890561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating locally advanced disease: an analysis of very large, hilar lymph node positive non-small cell lung cancer using the National Cancer Data Base.
    Moreno AC; Morgensztern D; Boffa DJ; Decker RH; Yu JB; Detterbeck FC; Wang Z; Rose MG; Kim AW
    Ann Thorac Surg; 2014 Apr; 97(4):1149-55. PubMed ID: 24582051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.